Omaveloxolone Patent Expiration

Omaveloxolone is used for treating Friedrich's ataxia by activating the NRF2 pathway to reduce oxidative stress in adults and adolescents aged 16 years and older. It was first introduced by Reata Pharmaceuticals Inc in its drug Skyclarys on Feb 28, 2023.


Omaveloxolone Patents

Given below is the list of patents protecting Omaveloxolone, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Skyclarys US11091430 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 Apr 20, 2029 Reata Pharms
Skyclarys US11919838 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 Apr 20, 2029 Reata Pharms
Skyclarys US8124799 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 Dec 03, 2029 Reata Pharms
Skyclarys US8440854 Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 Apr 20, 2029 Reata Pharms
Skyclarys US8993640 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof Apr 24, 2033 Reata Pharms
Skyclarys US9670147 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 Apr 20, 2029 Reata Pharms
Skyclarys US9701709 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof Apr 24, 2033 Reata Pharms


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Omaveloxolone's patents.

Given below is the list recent legal activities going on the following patents of Omaveloxolone.

Event Date Patent/Publication
Patent litigations
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8124799
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8440854
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US9670147
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US9701709
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US11091430
Second letter to regulating agency to determine regulatory review period 08 May, 2024 US8993640
Recordation of Patent eGrant 05 Mar, 2024 US11919838
Recordation of Patent Grant Mailed 05 Mar, 2024 US11919838
Patent eGrant Notification 05 Mar, 2024 US11919838
Email Notification 05 Mar, 2024 US11919838



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳